▎Edited by the WuXi AppTec content teamAccording to incomplete statistics from Innovation Radar, last week (March 31 to April 6) in the global health sectorA total of 14 financing events were disclosed, with a total amount exceeding 9.6 billion yuan.。In terms of amount, there were 7 financings of 100 million yuan or more.According to the disclosed financing rounds, there were 6 early-stage financings (before Series B) and 4 later-stage financings (Series B and onwards). A total of 5 companies in the biopharmaceutical field received financing, involving drug types including gene therapy, cell therapy, protein degradation therapy, etc.Isomorphic Labs Secures $600 Million in Funding
Keywords: AI Drugs
Latest Financing:$600 Million Series A
This roundInvestment Institutions:Alphabet, GV (Google Ventures), Thrive CapitalMarch 31,Isomorphic Labs, an AI drug design and development company, announces $600 million in funding.Isomorphic Labs aims toHarnessing the Power of AI to Reinvent and Accelerate Drug Discovery, bringing urgently needed treatments to patients worldwide. The company aims to leverage its groundbreaking AI drug design engine to achieve biomedical breakthroughs and is advancing drug design initiatives across multiple therapeutic areas and drug modalities.Since its establishment, the company has developed many next-generation AI models, which together form its unified AI drug design engine, applicable across multiple therapeutic areas and drug modalities. One example of a breakthrough model is AlphaFold 3, co-developed and released by Isomorphic Labs and Google DeepMind in May 2024, capable of accurately predicting the molecular structures and interactions of living organisms.AIRNA Completes $155 Million Series B Financing
Keywords:RNA Editing Therapy
Latest Financing:$155 Million Series B
This roundInvestment Institutions:ARCH Venture Partners, Forbion, ND Capital, Nextech Invest, RTW Investments, etc.April 1,AIRNA Announces Oversubscribed $155 Million Series B Financing. The company will use the funds from this roundAdvance its first RNA-editing candidate drug, AIR-001, for Alpha-1 Antitrypsin Deficiency (AATD) into Phase 1/2 clinical trials., and develop a series of innovative RNA-editing drugs targeting cardiometabolic and other diseases.AIRNA’s proprietary platform efficiently edits target RNA with safe and flexible drugs by leveraging natural mechanisms. Precise RNA editing aims to achieve functional cures for severe or chronic diseases by repairing harmful genetic variants or introducing beneficial ones. The press release noted that the company’s lead program has the potential to become a “best-in-class” therapy for treating alpha-1 antitrypsin deficiency.Atsena Secures $150 Million Oversubscribed Series C Financing
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Keyword: Gene Therapy
Latest Financing:$150 Million Series C
This roundInvestment Institutions:Abingworth, Bain Capital, Foundation Fighting Blindness, Hatteras Venture Partners, Wellington Management, etc.April 2,Atsena Therapeutics, a clinical-stage gene therapy company focused on harnessing the power of genetic medicine to reverse or prevent blindness, announced the successful completion of a $150 million oversubscribed Series C financing.The proceeds from financing will be used forAdvance Atsena's lead program ATSN-201 for the treatment of X-linked retinoschisis (XLRS)., a hereditary condition typically diagnosed in childhood that leads to blindness later in life. The proceeds will also support Atsena's potential ""First-in-class" preclinical pipeline, expanding the use of Atsena's novel adenovirus vector.Neurona Therapeutics Secures $102 Million in Financing
Keyword: Cell Therapy
Latest FusionResources:$102 million
This roundInvestment Institutions:Alexandria Venture Investments, Fidelity, The Column GroupApril 4,Neurona Therapeutics Announces $102 Million Raise to Advance Epilepsy Cell Therapy into Phase 3 Clinical TrialsThis California-based biotech company will use the funds toSupport its pipeline of allogeneic cell therapy candidates for chronic neurological diseasesAmong them, NRTX-1001 is currently in a Phase 1/2 trial in patients with drug-resistant mesial temporal lobe epilepsy (MTLE).Prazer Completes 290 Billion KRW Series B Financing
Keywords: Protein Degradation Therapy
LatestIntegrationResources:KRW 29 billion Series B
This roundInvestment Institutions:Company K Partners, K2 Investment, Kiwoom Investment, Mirae Asset Capital, Premier Partners, etc.April 1,Prazer Therapeutics Announces Completion of $29 Billion KRW Series B Financing to Advance Drug Development and Global CommercializationPrazer TherapeuticsDedicated to developing new drugs based on Targeted Protein Degradation (TPD) technologyThe company stated that existing TPD technologies use a limited number of E3 ubiquitin ligases to degrade proteins, whilePrazer's proprietary SPiDEM platform enables broader protein targeting using a variety of E3 ligases.The company expects that this will potentially overcome the limitations of existing PROTAC and molecular glue technologies and can target previously difficult-to-target sites, such as protein aggregates and membrane proteins.Readers, please star ⭐Chuangjian Hui to receive push notifications第一时间收到推送.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a正规 hospital.
Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media platforms, but unauthorized republication or reproduction by any media or organization in any form to other platforms is strictly prohibited. For authorization to republish, please contact:"Chuang Jian Hui"Contact us via WeChat Official Account comments.
More Data Content RecommendationsClick "InSee", Sharing Chuangjian Hui Health New Trends
